GBI Research's latest report, “Monoclonal
Antibodies - Global Trends in the Competitive, Technological and R&D
Landscape" discusses both the pipeline and market shares of
monoclonal antibodies (mAbs) across a number of therapy areas. mAbs are defined
as a collection of antibodies produced from a single B-cell clone. These
antibodies therefore share binding specificity towards a certain antigen, and
can be used as a means of targeted therapy within a number of indications
across the pharmaceutical market. mAbs have been in development in humans since
the mid-1970s, and a substantial number of mAb products have entered the
market. However, the majority are still in early-stage development, indicating
delays and setbacks in the progression of potential products. Despite this,
mAbs are the largest and fastest-growing segment of the biopharmaceutical
sector and account for almost half of the global revenue accrued from this area
annually. The pipeline is highly active, with 2,836 mAbs currently in
development. Most are at an early stage of development, with 76% at the
Discovery or Preclinical stage. Additionally, there are currently 85 mAb
programs in Phase III development, and 22 at the Pre-registration stage,
accounting for just under 4% of the total mAb pipeline.
This
CBR report provides a comprehensive view of the clinical, R&D, commercial
and competitive landscape of mAbs, and assesses key developments in
manufacturing and development, covering strategies to combat challenges
associated with the use of mAbs in human patients. While many mAbs that enter
the market achieve commercial success, a large proportion are stuck at
early-stage development: What strategies can be put in place to advance the
production of mAbs? What strategies can be used to improve both the affinity
and therapeutic efficacy of mAbs? What are the relative advantages and
disadvantages of each mAb type, and which hold the most promise? What proportion
of the overall mAb R&D pipeline is occupied by each mAb type? In which
therapy areas is there the highest level of R&D activity for mAbs? Which
stage of development accounts for the majority of the pipeline? How do mAbs fit
into the overall portfolios of companies developing them? What is the level of
involvement in mAbs research for the top 15 Big Pharma companies? Understand
the current status of the field of therapeutic mAbs and the relative clinical
and commercial success of currently marketed products, comprising Humira,
Remicade, Rituxan, Avastin, Herceptin, Opdivo, Lucentis, Stelara and Soliris.
Assess
the pipeline for mAbs split by therapy area, mAb type, and stage of
development. Additionally, a granular assessment of the pipeline is provided
across the four most active therapy areas for mAbs: oncology, infectious
diseases, immunology and central nervous system disorders. Gain a picture of
the current competitive landscape, with a detailed breakdown of the companies
actively involved in the mAb pipeline. Understand the level of involvement of
Big Pharma companies, and the extent to which mAbs fit into the portfolios of
companies in this field. Additionally, a highly granular breakdown of companies
developing mAbs is provided.
Key
Topics Covered in the Report:-
Monoclonal Antibodies Market Research Report
Monoclonal Antibodies Market Forecast
Monoclonal Antibodies Market Revenue
Monoclonal Antibodies Market Size
Monoclonal Antibodies Market Future Outlook
Monoclonal Antibodies Market Analysis
Monoclonal Antibodies Market Opportunities
Monoclonal Antibodies Market Competition
Monoclonal Antibodies Market Trends
Monoclonal Antibodies Market Shares
Monoclonal Antibodies Market Growth Analysis
For
more information on the research report, refer to below link: - https://www.kenresearch.com/healthcare/pharmaceuticals/monoclonal-antibodies-global-trends/142346-91.html
Related Reports by Ken Research:-
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-124 423 0204
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-124 423 0204
